Does low EPA and a high AA:EPA ratio reduce pro-resolving mediators and shift toward inflammation?

The relative balance of membrane-bound polyunsaturated fatty acids fundamentally dictates cellular inflammatory responses. When the arachidonic acid (AA)-to-eicosapentaenoic acid (EPA) ratio is high, metabolic pathways shift away from resolving inflammation toward active inflammatory signaling.

Enzymatic substrate competition

• Competitive inhibition: AA and EPA compete directly for the same catalytic cyclooxygenase (COX-1/COX-2) and lipoxygenase (5-LOX) enzymes.
• Pro-inflammatory bias: When EPA is low, AA dominates enzyme binding sites, resulting in the preferential synthesis of highly potent pro-inflammatory lipid mediators, specifically series-2 prostaglandins (PGE2) and series-4 leukotrienes (LTB4).
• The protective shift: Increasing EPA competitively inhibits AA oxygenation, shifting enzymatic output toward weaker, less inflammatory 3-series prostanoids (PGE3) and 5-series leukotrienes (LTB5).

Suppression of pro-resolving pathways

• Substrate-limited SPM synthesis: Specialized pro-resolving mediators (SPMs) require fatty acid precursors for biosynthesis. Low EPA deprives these pathways of the key intermediate 18-HEPE, reducing the generation of E-series resolvins (RvE1–RvE4) that actively promote tissue healing and the resolution of inflammation.
• Cytokine upregulation: A high AA-to-EPA ratio promotes the activation of nuclear factor kappa B (NF-κB), triggering the transcription and systemic release of classic pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β.

Bottom line

• A high AA-to-EPA ratio promotes a chronic pro-inflammatory state by outcompeting EPA for COX and LOX enzymes, which simultaneously increases the production of inflammatory eicosanoids (PGE2, LTB4) and downstream cytokines (TNF-α, IL-6) while suppressing essential E-series pro-resolving mediators.